Alarsin Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 0.60 M
as on 05-07-2024
- Paid Up Capital ₹ 0.10 M
as on 05-07-2024
- Company Age 69 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 8.72%
(FY 2022)
- Profit 9.46%
(FY 2022)
- Ebitda 4.14%
(FY 2022)
- Net Worth 10.51%
(FY 2022)
- Total Assets 9.99%
(FY 2022)
About Alarsin Pharmaceuticals (India)
The Corporate was formerly known as Alarsin Pharmaceuticals (India) Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.60 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Palash Patel, Satish Almaula, Ajay Patel, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239MH1955PTC009609
- Company No.
009609
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jul 1955
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Alarsin Pharmaceuticals (India)?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Palash Patel  | Director | 15-Oct-1998 | Current |
| Satish Almaula | Director | 01-Dec-1974 | Current |
| Ajay Patel | Director | 15-Jun-2004 | Current |
| Amar Patel | Director | 14-Feb-2005 | Current |
Financial Performance of Alarsin Pharmaceuticals (India).
Alarsin Pharmaceuticals (India) Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 8.72% increase. The company also saw a slight improvement in profitability, with a 9.46% increase in profit. The company's net worth Soared by an impressive increase of 10.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alarsin Pharmaceuticals (India)?
In 2019, Alarsin Pharmaceuticals (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Alarsin Marketing LlpActive 1 year 8 monthsPalash Patel, Satish Almaula and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Alarsin Pharmaceuticals (India)?
Unlock and access historical data on people associated with Alarsin Pharmaceuticals (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alarsin Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alarsin Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
